General Information of Drug (ID: DM2LYIN)

Drug Name
LX-7101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Phase 1/2 [1]
Cross-matching ID
PubChem CID
56962369
CAS Number
CAS 1192189-69-7
TTD Drug ID
DM2LYIN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Protein kinase (PK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [3]
LY2801653 DM0KJDY Biliary tract cancer 2C17 Phase 2 [3]
MGCD265 DMRPCF2 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [3]
RV-568 DM652CM Asthma CA23 Phase 2 [4]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [5]
Cyclocreatine DM1I7UO Virus infection 1A24-1D9Z Discontinued in Phase 1 [6]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase (PK) TTU8W4S NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01528111) Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health.
2 Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.